INTRODUCTION:The use of ustekinumab and vedolizumab as second-line therapies in patients with Crohn's disease (CD) in which tumour necrosis factor alpha inhibitors (TNFi) failed is still debated. The aim of this study was to compare, in a large multicenter observational retrospective cohort, the effectiveness of ustekinumab and vedolizumab as...
-
2022 (v1)PublicationUploaded on: February 4, 2024
-
2021 (v1)Publication
Background: Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.Objective: This study aimed to describe the long-term outcomes in a large cohort of patients on golimumab who had ulcerative colitis.Methods: Consecutive patients with active...
Uploaded on: February 14, 2024 -
2020 (v1)Publication
No description
Uploaded on: April 14, 2023